论文部分内容阅读
近几年,利用HBV慢性感染者血浆中的22nm球型颗粒制备疫苗已获成功,这些颗粒被称为HBsAg,它含有2种主要的病毒特异性成份即分子量为25,000的多肽(P25)和30,000的糖基化多肽(GP30)。本文报道完整22nm HBsAg颗粒、十二烷基硫酸钠(SDS)—变性的P25+GP30多肽和未变性的P25+GP30微胶粒等3种制剂的免疫原性。将上述3种制剂分别加盐悬液或铝凝胶佐剂,于腹腔内注射BALB/c小鼠,各免疫
In recent years, vaccines have been successful in the preparation of 22 nm spherical particles in the plasma of patients with chronic HBV infection. These particles, known as HBsAg, contain two major virus-specific components, namely, a polypeptide of 25,000 in molecular weight (P25) and 30,000 Glycosylated polypeptide (GP30). This article reports the immunogenicity of three preparations, a complete 22 nm HBsAg particle, SDS-denatured P25 + GP30 polypeptide and unmodified P25 + GP30 micelles. The above three kinds of formulations were added salt suspension or aluminum gel adjuvant, intraperitoneal injection of BALB / c mice, each immunization